CervoMed (CRVO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CRVO SEC filings page.
CervoMed Inc. (CRVO) reported $331K in revenue over the twelve months to Jun 30, 2026, down 95.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
CervoMed is spending like a development-stage company while revenue contracts, making financing and cash use more important than margins.
From FY2024 to FY2025, revenue fell58.9% while R&D rose16.1% , so development spending became increasingly detached from commercial scale. Administrative spending also increased, while 2025 operating cash flow of-$23.4M was less negative than the net loss of$27.0M ; that gap means accounting expenses exceeded cash outlays, but did not eliminate cash consumption.
Total assets fell
Financing cash flow fell from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of CervoMed Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
CervoMed Inc. held $20.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $23.4M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and CervoMed Inc. scores 33/100 among other emerging companies.
CervoMed Inc. had 9M shares outstanding at the end of fiscal year 2025, against 9M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and CervoMed Inc. scores 34/100 among other emerging companies.
CervoMed Inc. spent $21.8M on research and development in fiscal year 2025, which was 67.5% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and CervoMed Inc. scores 87/100 among other emerging companies.
CervoMed Inc. reported revenue of $4.0M in fiscal year 2025, against $9.7M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and CervoMed Inc. scores 16/100 among other emerging companies.
CervoMed Inc.'s operations used $23.4M of cash in fiscal year 2025, against $16.5M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and CervoMed Inc. scores 11/100 among other emerging companies.
CervoMed Inc.'s cash, cash equivalents and investments came to $20.9M at the end of fiscal year 2025, against $4.7M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and CervoMed Inc. scores 88/100 among other emerging companies.
CervoMed Inc. scores -4.60, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $97.7M against total assets of $22.9M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
CervoMed Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.
CervoMed Inc. reported a net loss of $27.0M while operations used $23.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
CervoMed Inc. generated $0 in revenue in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
CervoMed Inc. reported a net loss of $6.6M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
CervoMed Inc. held $22.5M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
CervoMed Inc.'s quarterly ROE was -28.6% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 9.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 46.4 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
CervoMed Inc. invested $4.3M in research and development in Q2 2026. This represents a decrease of 15.4% from the same quarter a year earlier. Against the prior quarter it is down 15.8%.
Not reported for Q2 2026.
Not reported for Q2 2026.
CRVO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0-100.0% | $0-100.0% | $9K-99.6% | $323K-83.4% | $1.8M-46.6% | $1.9M-18.3% | $2.2M-13.2% | $1.9M+27.1% |
| R&D Expenses | $4.3M-15.4% | $5.1M+6.2% | $5.8M-17.7% | $6.0M+17.9% | $5.1M+35.4% | $4.8M+71.9% | $7.1M+148.2% | $5.1M+186.1% |
| SG&A Expenses | $2.4M-27.8% | $3.0M+24.9% | $2.5M+8.4% | $2.3M+5.2% | $3.3M+30.0% | $2.4M+12.0% | $2.3M+9.5% | $2.2M-8.3% |
| Operating Income | -$6.7Mn/m | -$8.1Mn/m | -$8.3Mn/m | -$8.0Mn/m | -$6.6Mn/m | -$5.3Mn/m | -$7.2Mn/m | -$5.4Mn/m |
| Net Income | -$6.6Mn/m | -$8.0Mn/m | -$8.1Mn/m | -$7.7Mn/m | -$6.3Mn/m | -$4.9Mn/m | -$6.7Mn/m | -$4.8M-321.1% |
| EPS (Basic) | -$0.64n/m | -$0.86n/m | -$0.88n/m | -$0.84n/m | -$0.70n/m | -$0.56n/m | -$0.80n/m | -$0.55 |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$0.55 |
| Diluted Shares (Avg) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 9M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EBITDA, Interest Expense, Income Tax.
CRVO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $26.0M-31.7% | $15.1M-60.8% | $22.9M-46.9% | $30.6M-37.4% | $38.1M-28.4% | $38.6M+382.4% | $43.1M+332.0% | $48.9M+306.1% |
| Current Assets | $26.0M-31.7% | $15.1M-60.8% | $22.9M-46.9% | $30.6M-37.3% | $38.1M-19.5% | $38.6M+384.3% | $43.1M+332.3% | $48.8M+312.1% |
| Cash & Equivalents | $22.5M+170.0% | $7.9M-24.4% | $8.2M-8.5% | $9.4M+21.9% | $8.3M-16.9% | $10.5M+64.9% | $9.0M+15.5% | $7.7M-25.7% |
| Short-Term Investments | $2.5M-90.2% | $5.0M-79.9% | $12.6M-57.8% | $17.9M-54.1% | $25.2M-28.1% | $24.7Mn/m | $29.9Mn/m | $38.9Mn/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0-100.0% | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $3.0M-34.7% | $4.5M+14.1% | $4.7M+20.0% | $4.6M+41.7% | $4.6M+44.4% | $3.9M+48.2% | $3.9M+49.4% | $3.2M+31.8% |
| Current Liabilities | N/A | N/A | $4.7M+20.0% | N/A | N/A | N/A | $3.9M | N/A |
| Non-Current Liabilities | N/A | N/A | $0n/m | N/A | N/A | N/A | $0 | N/A |
| Total Equity | $23.0M-31.3% | $10.6M-69.3% | $18.2M-53.5% | $26.0M-43.0% | $33.4M-33.1% | $34.6M+549.0% | $39.2M+431.4% | $45.6M+376.7% |
| Retained Earnings | -$112.2Mn/m | -$105.7Mn/m | -$97.7Mn/m | -$89.6Mn/m | -$81.9Mn/m | -$75.6Mn/m | -$70.7Mn/m | -$64.0Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
CRVO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.9Mn/m | -$8.0Mn/m | -$6.6Mn/m | -$6.5Mn/m | -$6.5Mn/m | -$3.9Mn/m | -$8.1Mn/m | -$4.9Mn/m |
| Stock-Based Compensation | $362K-27.1% | $349K-3.3% | N/A | $292K+7.6% | $497K-14.1% | $361K+65.5% | N/A | $271K+148.4% |
| Investing Cash Flow | $2.5Mn/m | $7.7M+42.9% | $5.4M-42.3% | $7.6M+191.3% | -$255Kn/m | $5.4Mn/m | $9.3Mn/m | $2.6Mn/m |
| Financing Cash Flow | $18.9M+312.2% | $14Kn/m | $0n/m | $0n/m | $4.6M | $0 | $0n/m | -$13K-100.1% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
CRVO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | -95479.2% | -2493.8% | -376.4% | -276.6% | -334.9% | -278.2% |
| Net Margin | N/A | N/A | -92680.4% | -2395.3% | -356.1% | -255.2% | -310.2% | -245.1% |
| Return on Equity | -28.6%-9.9pp | -75.0%-60.9pp | -44.4%-27.3pp | -29.7%-19.3pp | -18.7%-14.1pp | -14.1%+33.0pp | -17.1%+14.9pp | -10.4%-32.9pp |
| Return on Assets | -25.3%-8.9pp | -52.7%-40.0pp | -35.4%-19.8pp | -25.2%-15.5pp | -16.4%-12.1pp | -12.7%+18.8pp | -15.6%+8.1pp | -9.7%-27.6pp |
| Current Ratio | N/A | N/A | 4.91-6.2x | N/A | N/A | N/A | 11.11 | N/A |
| Liabilities-to-Equity | 0.130.0x | 0.42+0.3x | 0.26+0.2x | 0.18+0.1x | 0.14+0.1x | 0.11-0.4x | 0.10-0.3x | 0.07-0.2x |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.000.0x | 0.010.0x | 0.050.0x | 0.05-0.2x | 0.05-0.2x | 0.04-0.1x |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| CervoMed Inc. CRVO | FY2025 | $4.0M | -$27.0M | N/A | $33.6M | 45/100 |
| Acumen Pharmaceuticals, Inc. ABOS | FY2025 | N/A | -$121.3M | N/A | $164.2M | — |
| Immunic, Inc. IMUX | FY2025 | N/A | -$97.2M | N/A | $99.3M | — |
| ANEBULO PHARMAC INC ANEB | FY2025 | N/A | -$8.5M | N/A | $11.2M | — |
| Ovid Therapeutics Inc. OVID | FY2025 | $7.3M | -$17.4M | N/A | $420.9M | 66/100 |
| XBiotech Inc XBIT | FY2025 | N/A | -$45.5M | N/A | $56.4M | — |
Where CervoMed Inc. Ranks
Frequently Asked Questions
What is CervoMed Inc.'s annual revenue?
CervoMed Inc. (CRVO) reported $4.0M in total revenue for fiscal year 2025. This represents a -58.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is CervoMed Inc.'s revenue growing?
CervoMed Inc. (CRVO) revenue declined by 58.9% year-over-year, from $9.7M to $4.0M in fiscal year 2025.
Is CervoMed Inc. profitable?
No, CervoMed Inc. (CRVO) reported a net loss of $30.3M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $27.0M.
What is CervoMed Inc.'s return on equity (ROE)?
CervoMed Inc. (CRVO) has a return on equity of -148.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is CervoMed Inc.'s operating cash flow?
CervoMed Inc. (CRVO) recorded an outflow of $23.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are CervoMed Inc.'s total assets?
CervoMed Inc. (CRVO) had $22.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does CervoMed Inc. spend on research and development?
CervoMed Inc. (CRVO) invested $21.8M in research and development during fiscal year 2025.
What is CervoMed Inc.'s current ratio?
CervoMed Inc. (CRVO) had a current ratio of 4.91 as of fiscal year 2025, which is generally considered healthy.
What is CervoMed Inc.'s liabilities-to-equity ratio?
CervoMed Inc. (CRVO) had a liabilities-to-equity ratio of 0.26 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is CervoMed Inc.'s return on assets (ROA)?
CervoMed Inc. (CRVO) had a return on assets of -117.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is CervoMed Inc.'s P/E ratio?
CervoMed Inc. (CRVO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $33.6M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is CervoMed Inc.'s price-to-sales ratio?
CervoMed Inc. (CRVO) trades at 101x sales, its market capitalization divided by $331K revenue, trailing 12 months to June 30, 2026. The market capitalization is $33.6M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does CervoMed Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, CervoMed Inc. (CRVO) held $20.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $23.4M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is CervoMed Inc.'s Altman Z-Score?
CervoMed Inc. (CRVO) has an Altman Z-Score of -4.60, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is CervoMed Inc.'s Piotroski F-Score?
CervoMed Inc. (CRVO) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are CervoMed Inc.'s earnings high quality?
CervoMed Inc. (CRVO) reported a net loss of $27.0M while operations used $23.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is CervoMed Inc.?
CervoMed Inc. (CRVO) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.